Lowest-Rated StocksLowest-RatedNYSE:BAX Baxter International (BAX) Stock Price, News & Analysis $38.96 +0.14 (+0.36%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$38.41▼$39.4850-Day Range$32.85▼$38.9752-Week Range$31.01▼$44.01Volume6.15 million shsAverage Volume4.22 million shsMarket Capitalization$19.85 billionP/E Ratio7.49Dividend Yield2.98%Price Target$41.73 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Baxter International alerts: Email Address Baxter International MarketRank™ Stock AnalysisAnalyst RatingHold2.09 Rating ScoreUpside/Downside7.1% Upside$41.73 Price TargetShort InterestHealthy1.72% of Shares Sold ShortDividend StrengthModerateBased on Four FactorsSustainability-1.95Upright™ Environmental ScoreNews Sentiment0.72Based on 7 Articles This WeekInsider TradingN/AProj. Earnings Growth8.11%From $2.96 to $3.20 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.58 out of 5 starsMedical Sector78th out of 910 stocksSurgical & Medical Instruments Industry9th out of 95 stocks 2.0 Analyst's Opinion Consensus RatingBaxter International has received a consensus rating of Hold. The company's average rating score is 2.09, and is based on 2 buy ratings, 8 hold ratings, and 1 sell rating.Amount of Analyst CoverageBaxter International has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Baxter International's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.72% of the outstanding shares of Baxter International have been sold short.Short Interest Ratio / Days to CoverBaxter International has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Baxter International has recently decreased by 11.98%, indicating that investor sentiment is improving significantly. Previous Next 2.5 Dividend Strength Dividend YieldBaxter International pays a meaningful dividend of 3.09%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthBaxter International does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Baxter International is 22.31%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Baxter International will have a dividend payout ratio of 36.25% next year. This indicates that Baxter International will be able to sustain or increase its dividend.Read more about Baxter International's dividend. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBaxter International has received a 55.71% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Vaccines (J07)", "Blood plasma proteins", and "Anaesthetics (N01)" products. See details.Environmental SustainabilityThe Environmental Impact score for Baxter International is -1.95. Previous Next 2.1 News and Social Media Coverage News SentimentBaxter International has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Baxter International this week, compared to 7 articles on an average week.Search InterestOnly 27 people have searched for BAX on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Baxter International to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Baxter International insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.21% of the stock of Baxter International is held by insiders.Percentage Held by Institutions90.19% of the stock of Baxter International is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Baxter International's insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Baxter International are expected to grow by 8.11% in the coming year, from $2.96 to $3.20 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Baxter International is 7.49, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.87.Price to Earnings Ratio vs. SectorThe P/E ratio of Baxter International is 7.49, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 115.64.Price to Earnings Growth RatioBaxter International has a PEG Ratio of 1.28. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioBaxter International has a P/B Ratio of 2.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Baxter International's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.I call these Nvidia’s “Silent Partners.” About Baxter International Stock (NYSE:BAX)Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.Read More BAX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BAX Stock News HeadlinesSeptember 5 at 3:16 PM | msn.comMedtronic Recalls Some Video Laryngoscopes Due To Increased Risk For Battery Overheat, ExplosionSeptember 5 at 3:16 PM | markets.businessinsider.comBaxter International (BAX) Receives a Hold from CitiSeptember 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…September 3, 2024 | globenewswire.comSpectral Medical Provides August Tigris Trial UpdateAugust 30, 2024 | americanbankingnews.comQ3 2024 EPS Estimates for Baxter International Inc. (NYSE:BAX) Boosted by Zacks ResearchAugust 29, 2024 | seekingalpha.comBaxter: Fire-Sale For Its Kidney CareAugust 29, 2024 | finance.yahoo.comBaxter to Present at 2024 Wells Fargo Healthcare ConferenceAugust 28, 2024 | americanbankingnews.comReviewing Baxter International (NYSE:BAX) and Presbia (OTCMKTS:LENSF)September 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.August 28, 2024 | americanbankingnews.comComparing Baxter International (NYSE:BAX) and Presbia (OTCMKTS:LENSF)August 26, 2024 | stocknews.com3 High-Growth MedTech Stocks to BuyAugust 23, 2024 | msn.comBaxter wants Exeter to get more 'competitive edge'August 22, 2024 | sg.finance.yahoo.comBaxter International Inc (BTL.HM)August 16, 2024 | marketwatch.comBaxter International Inc. stock underperforms Friday when compared to competitors despite daily gainsAugust 13, 2024 | msn.comBaxter to sell its kidney-care business in a $3.8 billion deal to Carlyle GroupAugust 13, 2024 | markets.businessinsider.comBaxter Agrees To Sell Its Kidney Care Segment To Carlyle For $3.8 BlnAugust 13, 2024 | markets.businessinsider.comBaxter International Hold Rating Maintained Amidst Modest Growth Projections Post-Vantive SaleAugust 13, 2024 | msn.comBaxter to divest kidney care segment to Carlyle for $3.8BSee More Headlines Receive BAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Baxter International and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Ex-Dividend for 7/1 Dividend5/31/2024Dividend Payable7/01/2024Last Earnings8/06/2024Ex-Dividend for 10/1 Dividend8/30/2024Today9/07/2024Dividend Payable10/01/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNYSE:BAX CUSIP07181310 CIK10456 Webwww.baxter.com Phone(224) 948-2000Fax224-948-1813Employees60,000Year Founded1931Price Target and Rating Average Stock Price Target$41.73 High Stock Price Target$54.00 Low Stock Price Target$30.00 Potential Upside/Downside+7.1%Consensus RatingHold Rating Score (0-4)2.09 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)$5.20 Trailing P/E Ratio7.49 Forward P/E Ratio13.16 P/E Growth1.28Net Income$2.66 billion Net Margins16.51% Pretax Margin-0.50% Return on Equity18.06% Return on Assets5.21% Debt Debt-to-Equity Ratio1.35 Current Ratio1.40 Quick Ratio0.91 Sales & Book Value Annual Sales$15.00 billion Price / Sales1.32 Cash Flow$5.38 per share Price / Cash Flow7.24 Book Value$15.11 per share Price / Book2.58Miscellaneous Outstanding Shares509,580,000Free Float508,510,000Market Cap$19.85 billion OptionableOptionable Beta0.59 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Jose E. Almeida (Age 62)Chairman of the Board, President & CEO Comp: $3.62MMr. Joel T. Grade (Age 53)Executive VP & CFO Comp: $829.82kMs. Heather Knight (Age 52)Executive VP & Group President of Medical Products and Therapies Comp: $1.63MMr. Alok Sonig B.E. (Age 52)Mba, Executive VP & Group President of Pharmaceuticals Comp: $1.56MMr. Christopher A. Toth (Age 44)Executive VP & Group President of Kidney Care Comp: $5.26MMs. Tobi Karchmer M.D.M.S., Senior VP and Chief Medical & Scientific OfficerMs. Clare TrachtmanVice President of Investor RelationsMr. David S. Rosenbloom (Age 64)Executive VP & General Counsel Comp: $776.51kMs. Stacey Eisen?Senior Vice President, Chief Communications Officer & Corporate Marketing?Ms. Jeanne K. Mason Ph.D. (Age 68)?Executive VP & Chief Human Resources Officer Comp: $1.99MMore ExecutivesKey CompetitorsBecton, Dickinson and CompanyNYSE:BDXEdwards LifesciencesNYSE:EWIDEXX LaboratoriesNASDAQ:IDXXResMedNYSE:RMDDexComNASDAQ:DXCMView All CompetitorsInstitutional OwnershipPensioenfonds Rail & OVSold 13,365 shares on 8/30/2024Ownership: 0.168%Birmingham Capital Management Co. Inc. ALSold 300 shares on 8/28/2024Ownership: 0.003%Teachers Retirement System of The State of KentuckySold 1,217 shares on 8/26/2024Ownership: 0.008%SkyView Investment Advisors LLCBought 1,248 shares on 8/16/2024Ownership: 0.002%Toronto Dominion BankSold 3,031 shares on 8/15/2024Ownership: 0.029%View All Institutional Transactions Should I Buy Baxter International Stock? BAX Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Baxter International Inc.: Baxter International Inc. develops and provides a portfolio of healthcare products worldwide, which is a growing industry with increasing demand for healthcare services. The company operates through multiple segments, including Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care, providing diversification in revenue streams. Recent developments in the healthcare industry have shown a trend towards innovation and technological advancements, which Baxter International Inc. is well-positioned to capitalize on. Baxter International Inc. has a strong track record of product development and innovation, which can lead to competitive advantages in the market. With the current stock price of Baxter International Inc., investors have the opportunity to invest in a company with growth potential at a reasonable valuation. Cons Investors should be bearish about investing in Baxter International Inc. for these reasons: While the healthcare industry is growing, it is also highly regulated and subject to changes in government policies, which can impact the company's operations and profitability. Competition in the healthcare sector is intense, with many established players and new entrants vying for market share, which could potentially affect Baxter International Inc.'s market position. Investing in healthcare companies can be risky due to factors such as regulatory approvals, product recalls, and litigation risks, which could negatively impact the company's financial performance. Fluctuations in healthcare spending and reimbursement rates can affect Baxter International Inc.'s revenue and profitability, making it susceptible to economic downturns and changes in healthcare policies. While Baxter International Inc. has a strong track record, past performance is not indicative of future results, and investors should carefully consider the risks associated with investing in the company. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, August 19, 2024. Please send any questions or comments about these Baxter International pros and cons to contact@marketbeat.com. BAX Stock Analysis - Frequently Asked Questions How have BAX shares performed this year? Baxter International's stock was trading at $38.66 at the start of the year. Since then, BAX stock has increased by 0.8% and is now trading at $38.96. View the best growth stocks for 2024 here. How were Baxter International's earnings last quarter? Baxter International Inc. (NYSE:BAX) posted its quarterly earnings results on Tuesday, August, 6th. The medical instruments supplier reported $0.68 EPS for the quarter, topping analysts' consensus estimates of $0.66 by $0.02. The firm's revenue for the quarter was up 2.8% on a year-over-year basis. Read the conference call transcript. What is José (Joe) Almeida's approval rating as Baxter International's CEO? 506 employees have rated Baxter International Chief Executive Officer José (Joe) Almeida on Glassdoor.com. José (Joe) Almeida has an approval rating of 85% among the company's employees. Does Baxter International have any subsidiaries? The following companies are subsidiaries of Baxter International: Cheetah Medical, ApaTech Limited, Baxter AO, Baxter Belgium SPRL, Baxter (China) Investment Co. Ltd, Baxter Company Ltd, Baxter Corporation (Canada), and others. Who are Baxter International's major shareholders? Top institutional shareholders of Baxter International include Bank of New York Mellon Corp (1.33%), LSV Asset Management (0.82%), Shapiro Capital Management LLC (0.64%) and Thompson Siegel & Walmsley LLC (0.39%). Insiders that own company stock include Jeanne K Mason, Albert P L Stroucken, Jacqueline Kunzler and Brian Stevens. View institutional ownership trends. How do I buy shares of Baxter International? Shares of BAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Baxter International own? Based on aggregate information from My MarketBeat watchlists, some other companies that Baxter International investors own include Xtrackers California Municipal Bond ETF (CA), Johnson & Johnson (JNJ), Pfizer (PFE), Cisco Systems (CSCO), Intel (INTC) and Abbott Laboratories (ABT). This page (NYSE:BAX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Baxter International Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Baxter International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BAX Stock Alerts